

Published in final edited form as:

*Blood*. 2012 December 20; 120(26): 5134–5142. doi:10.1182/blood-2012-07-443218.

## Small sizes and indolent evolutionary dynamics challenge the potential role of *P2RY8-CRLF2*–harboring clones as main relapse-driving force in childhood ALL

Maria Morak<sup>1</sup>, Andishe Attarbaschi<sup>2</sup>, Susanna Fischer<sup>1</sup>, Christine Nassimbeni<sup>1</sup>, Reinhard Grausenburger<sup>1</sup>, Stephan Bastelberger<sup>1</sup>, Stefanie Krentz<sup>3</sup>, Gunnar Cario<sup>4</sup>, David Kasper<sup>5</sup>, Klaus Schmitt<sup>6</sup>, Lisa J. Russell<sup>7</sup>, Ulrike Pötschger<sup>1</sup>, Martin Stanulla<sup>4</sup>, Conny Eckert<sup>3</sup>, Georg Mann<sup>2</sup>, Oskar A. Haas<sup>1,2</sup>, and Renate Panzer-Grümayer<sup>1,2</sup>

<sup>1</sup>Children's Cancer Research Institute, St Anna Kinderkrebsforschung, Vienna, Austria

<sup>2</sup>St Anna Kinderspital, Medical University Vienna, Vienna, Austria

<sup>3</sup>Department of Pediatrics, Division of Oncology and Hematology, Charité-Universitätsmedizin Berlin, Campus Virchow Klinikum, Berlin, Germany

<sup>4</sup>Department of Pediatrics, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany

<sup>5</sup>Department of Pediatric and Adolescent Medicine, Medical University Vienna, Vienna, Austria

<sup>6</sup>Children's Hospital, Linz, Austria

<sup>7</sup>Leukemia Research Cytogenetics Group, Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne, United Kingdom

### Abstract

The *P2RY8-CRLF2* fusion defines a particular relapse-prone subset of childhood acute lymphoblastic leukemia (ALL) in Italian Association of Pediatric Hematology and Oncology Berlin-Frankfurt-Münster (AIEOP-BFM) 2000 protocols. To investigate whether and to what extent different clone sizes influence disease and relapse development, we quantified the genomic *P2RY8-CRLF2* fusion product and correlated it with the corresponding *CRLF2* expression levels in patients enrolled in the BFM-ALL 2000 protocol in Austria. Of 268 cases without recurrent chromosomal translocations and high hyperdiploidy, representing approximately 50% of all cases, 67 (25%) were *P2RY8-CRLF2* positive. The respective clone sizes were  $\geq 20\%$  in 27% and  $< 20\%$  in 73% of them. The cumulative incidence of relapse of the entire fusion-positive group was clone size independent and significantly higher than that of the fusion-negative group ( $35\% \pm 8\%$  vs

---

Copyright 2011 by The American Society of Hematology; all rights reserved.

Correspondence: Renate Panzer-Grümayer, Leukemia Biology Group, Children's Cancer Research Institute, Zimmermannplatz 10, Room 110, 1090 Vienna, Austria; rena.panzer@ccri.at.

**Authorship:** M.M. designed and performed experiments, interpreted data, and drafted the manuscript; A.A. provided patient material and clinical data and performed respective analyses; S.F., C.N., R.G., S.B., and S.K. performed experiments; L.J.R. performed FISH; C.E., K.S., G.C., and M.S. contributed patient samples and clinical and biological data; D.K. provided Guthrie cards; U.P. performed statistical analyses; G.M. was responsible for the clinical study, provided patient samples and clinical data, and contributed to the design of the project; O.A.H. interpreted data, contributed to study design, and wrote the manuscript; R.G.-P. conceived and supervised the study, interpreted data, and wrote the manuscript; and all authors read and agreed to the final version of the manuscript.

Conflict-of-interest disclosure: The authors declare no competing financial interests.

13%  $\pm$  3%,  $P = .008$ ) and primarily confined to the non-high-risk group. Of 22 *P2RY8-CRLF2*-positive diagnosis/relapse pairs, only 4/8 had the fusion-positive dominant clone conserved at relapse, whereas none of the original 14 fusion-positive small clones reappeared as the dominant relapse clone. We conclude that the majority of *P2RY8-CRLF2*-positive clones are small at diagnosis and virtually never generate a dominant relapse clone. Our findings therefore suggest that *P2RY8-CRLF2*-positive clones do not have the necessary proliferative or selective advantage to evolve into a disease-relevant relapse clone.

## Introduction

B-cell precursor acute lymphoblastic leukemias (BCP-ALLs) with either a genomic rearrangement or deregulated expression of the cytokine receptor-like factor 2 (*CRLF2*), or both, practically never concur with *ETV6-RUNX1*, *MLL*, *TCF3*, or *BCR-ABL* fusions.<sup>1-6</sup> They are primarily classified as standard (SR) or high risk (HR) in Children's Oncology Group (COG) protocols and as corresponding SR and intermediate risk (IR) in Italian Association of Pediatric Hematology and Oncology Berlin-Frankfurt-Münster (AIEOP-BFM) protocols, with a significantly increased risk of relapse in non-Down syndrome (DS) patients.<sup>1,2,6-9</sup>

The 2 most prominent genomic rearrangements are those that either juxtapose the first noncoding exon of *P2RY8* to the *CRLF2* coding region or put the latter under the control of the *IGH@* gene enhancer.<sup>1-3,10,11</sup> The *P2RY8-CRLF2* fusion in particular results from an approximately 320-kb large interstitial deletion within the pseudoautosomal region 1 (PAR1) that is located on the short arm of both sex chromosomes. Apart from rare *CRLF2*-activating mutations and additional copies of the respective gene-containing chromosomal region, no other consistent genetic factors are currently known to be associated with a *CRLF2* overexpression.<sup>1,4-6,8,12</sup> With an incidence of 5% to 7%, cases with a *P2RY8-CRLF2* fusion are 2 to 5 times as common as those with an *IGH@-CRLF2* translocation and at > 50% they are particularly frequent in DSALL patients.<sup>1-3,10,11</sup>

Of note, in AIEOP-BFM studies apparently only half of the *P2RY8-CRLF2* fusion-positive cases overexpress *CRLF2*.<sup>8</sup> Conversely, only half of the overexpressing cases in these studies, and also those from COG focusing on HR ALL cases, carry a *CRLF2* genomic lesion.<sup>1,4-8</sup> This intriguing discrepancy raised the question of why not all *CRLF2* fusions cause a similar *CRLF2* overexpression, and consequently, whether the fusion or the overexpression might be the preferred predictive factor. The discussion was fueled by the heterogeneous results that were obtained by the various study groups, because they used different patient cohorts and numbers, protocols and observation periods, and screening approaches.<sup>1-8,10,11</sup> *P2RY8-CRLF2*-positive cases, for example, can be ascertained at the genomic level by either fluorescence in situ hybridization (FISH), genomic PCR, or multiplex ligation-dependent probe amplification, and on the RNA level with RT-PCR. *CRLF2* expression levels, in contrast, can be determined by various absolute and relative measurement methods with arbitrary cut-off levels for overexpression.

The BFM group originally screened for high *CRLF2* expression and found that especially patients with a concurring *P2RY8-CRLF2* fusion in the non-HR group had a significantly

increased relapse risk.<sup>1</sup> These findings were recently corroborated by the AIEOP-BFM 2000 study that concluded that the *P2RY8-CRLF2* fusion is the relevant factor.<sup>8</sup> Thus, at least for the non-HR groups in the AIEOP-BFM protocols, the clinically most crucial problem in this context seems to have been answered for the time being. Nevertheless, it remains difficult to understand why and how such genomic lesions, even without the appropriate simultaneous evidence of a corresponding functional correlate in form of *CRLF2* overexpression, should be able to increase the relapse risk. The most likely explanation is that the extent of the overall expression levels merely reflects or correlates with fluctuating proportions of the fusion-positive clones. Along these lines, one also would expect that fusion-positive clones should have either a selective or proliferative advantage, or both, to be able to directly contribute to disease progression and relapse development.

We addressed these questions with the help of unbiased and highly sensitive qualitative and quantitative PCR analyses to determine the respective clone sizes in the diagnostic and relapse samples, correlated the ensuing results with the corresponding *CRLF2* expression levels, and we also checked whether *P2RY8-CRLF2* fusions were already present in Guthrie card blood samples that had been taken at birth.

## Methods

### Patient samples

Frozen viable cells or DNA and RNA were obtained from the diagnostic, remission, and relapse bone marrow samples of children and adolescents with BCP-ALL that had been consecutively enrolled in the BFM ALL 2000 study in Austria over a 10-year period (2000-2010). Leukemia samples (with at least 85% blasts) were obtained from the Austrian Study center on institutional review approval and with approval of the ethics committee. Informed consent for tissue banking and research studies was obtained from patients, their parents, legal guardians, or a combination in accordance with the Declaration of Helsinki. Cytogenetic and genetic characterization of all samples was performed as a routine diagnostic workup. Final risk assignment was performed according to published clinical and minimal residual disease criteria.<sup>13-15</sup>

### Detection of *P2RY8-CRLF2*

**Genomic PCR**—Genomic PCR for the PAR1 deletion that results in a *P2RY8-CRLF2* fusion was performed as described previously.<sup>2</sup> In brief, 100 ng of genomic DNA was amplified using Hot-start Phusion High-Fidelity DNA polymerase II (Biozym) on a C1000 thermal cycler (Bio-Rad Laboratories). Primer sequences and PCR conditions can be found in supplemental Table 1. PCR products were separated on agarose gels, purified (QIAquick PCR purification kit; QIAGEN), and sequenced from both sides (Eurofins MWG Operon). Sequences were confirmed from a second independent PCR amplification.

**Long-distance multiplex PCR**—A set of 21 primers, covering intron 1 of *P2RY8* and positioned at a distance of 1500 to 2000 bp apart from each other, and a second set of 30 primers, distributed over a 50-kb region upstream of *CRLF2* exon 1, were designed (sequences and PCR conditions are available on request). Genomic DNA from 6 transcript-

positive cases without the common *P2RY8-CRLF2* fusion was amplified with various primer mixes containing 10 forward (or reverse) primers each and 1 of the reverse (or forward) primers. PCR products were visualized on agarose gels and sequenced. Sequences were verified from a second independent PCR amplification.

**Quantification of genomic P2RY8-CRLF2**—The amounts of genomic fusion were determined by TaqMan PCR with a 7500 real-time PCR system (Applied Biosystems) using the following primer-probe combination: P2RY8\_q\_fw, CRLF2\_q\_rv, and P-C\_q\_pr (corresponding primer sequences are shown in supplemental Table 1). A standard curve with 10-log dilution steps from  $1 \times 10^{-1}$  to  $1 \times 10^{-5}$  from 1 case with one copy of the *P2RY8-CRLF2* in virtually all leukemia cells was used for quantification of the genomic fusion in test samples. Samples were run in triplicates. In the 2 relapse samples with a blast count of < 85%, the genomic fusion levels were related to the respective blast counts.

**PCR for P2RY8-CRLF2 transcripts**—Total leukemic cell RNA was extracted using the RNeasy mini kit (QIAGEN). We reverse transcribed 2  $\mu$ g of RNA with Moloney murine leukemia virus reverse transcriptase (Promega) and amplified using Hot-start Phusion HF polymerase II using published primers.<sup>2</sup> Cycling conditions were optimized to detect low abundant transcripts (provided in supplemental Table 1).

**Quantitative real-time PCR for CRLF2 expression**—*CRLF2* and endogenous control *ALAS1* gene expression levels were quantified by quantitative (q)RT-PCR using a 7500 real-time PCR system (Applied Biosystems) and the following primer and probe combinations: CRLF2\_q\_fw, CRLF2\_q\_rv and CRLF2\_q\_pr, as well as ALAS1\_q\_fw, ALAS1\_q\_rv, and ALAS1\_q\_pr (primer sequences are shown in supplemental Table 1). Samples were run in triplicates, and transcript levels are indicated as fold changes relative to an arbitrary calibrator (mean *CRLF2* expression of peripheral blood mononuclear cells [MNCs] from 8 healthy controls) using comparative Ct analysis ( $2^{-Ct}$ ) after normalization to endogenous *ALAS1* expression. The standard curve was obtained by dilutional series of RNA/cDNA extracted from the erythropoietin-stimulated cell line TF1 (DSMZ).

To compare the fold changes obtained from this qRT-PCR, quantification of *CRLF2* expression also was performed using inventoried assays for *CRLF2* (Hs00845692\_m1) and *EEF2* (Hs00157330\_m1; both from Applied Biosystems). The assays were run at the default conditions recommended by the manufacturer. Samples were run in triplicates, and transcript levels were calculated as  $-Ct$  values, essentially as described by Chen et al.<sup>6</sup> The same cut-off of  $-8$   $-Ct$  for *CRLF2* overexpression was applied.

**Detection of the P2RY8-CRLF2 fusion in Guthrie cards**—DNA was extracted from one-third of a neonatal blood spot (Guthrie card), essentially as described previously with minor variations (see supplemental Figure 5).<sup>16-18</sup> From cases with the previously published breakpoints, the genomic fusion was determined in whole genome-amplified Guthrie card DNA by TaqMan qRT-PCR as described in “Quantification of genomic *P2RY8-CRLF2*.” For the case with the newly identified breakpoint, a patient-specific nested 2-round PCR was established using a standard curve (10-log dilutions) from the respective diagnostic leukemia DNA. P2RY8\_fw1 and CRLF2\_rv10 were used for the first round and P2RY8\_fw10 was

used with a patient-specific reverse primer for the second-round PCR (primer sequences in supplemental Table 1). The patient-specific primer was placed over the breakpoint. PCR products were size separated on agarose gels, purified, and sequenced.

### Statistical analyses

Associations between categorical variables were examined using Fisher exact test. Event-free survival (EFS) and overall survival (OS) were analyzed according to the Kaplan-Meier method and compared by the log-rank test.<sup>19</sup> The cumulative incidence of relapse (CIR) functions were calculated by the method of Kalbfleish and Prentice and compared using the Gray test.<sup>20,21</sup>

Spearman rank correlation was used to study the correlation between genomic *P2RY8-CRLF2* amounts and *CRLF2* expression and between the corresponding *CRLF2* expression levels determined by 2 different methods.

## Results

### Screening for genomic *P2RY8-CRLF2* breakpoints and identification of novel deletion breakpoints upstream of *CRLF2*

We restricted our screening to those 277 BCP-ALL cases in the Austrian ALL BFM 2000 treatment protocol (n = 555, including 25 individuals with DS) that neither had an HD karyotype nor an *MLL*, *BCR-ABL*, or *ETV6-RUNX1* gene rearrangement. Moreover, we excluded all 8 cases with an *IGH@-CRLF2* translocation from these analyses. DNA was available from 268 (97%) of these cases, including 20 with DS. The clinical and biologic data of these cases are summarized in Table 1.

Applying a breakpoint region-specific genomic PCR, we primarily identified 61/268 (22.8%) cases with a *P2RY8-CRLF2* fusion (Figure 1A). In line with previous reports, DNA sequence analysis revealed unique breakpoints with the insertion of template independent nucleotides.<sup>2,10,22</sup>

Screening for the corresponding *P2RY8-CRLF2* transcripts in 234/268 (87%) cases with available RNA confirmed the presence of the genomic fusion in all instances, but this screening also revealed a distinct RT-PCR product in another 6 (including 3 with DS), apparently fusion breakpoint-negative, cases (Figure 1B). With the help of long-distance multiplex PCR, we subsequently discovered 2 new breakpoints 2.1 kb and 0.1 kb upstream of *CRLF2* exon 1 (Figure 1C and supplemental Figure 1, sequences submitted to dbVar, study accession nstd72). In line with the previously described breakpoints,<sup>2,22</sup> they had a sequence pattern that indicates that they were also V(D)J recombination mediated. Comprising approximately 10% of the entire fusion-positive cohort, these new breakpoints increased the frequency of *P2RY8-CRLF2* cases to 67/268 (25%), translating into an overall frequency of 12.1% in BCP-ALL cases, a figure that is approximately twice as high as the 5% to 7% reported by others.<sup>1,3,5,11</sup> Fifteen of those *P2RY8-CRLF2*-positive cases had a DS, relating to 60% of the entire ALL DS group, a rate that is comparable to the 50% reported previously.<sup>2,10</sup>

In contrast to other studies,<sup>1,5,8</sup> we found that *P2RY8-CRLF2*-positive cases were considerably younger than fusion-negative cases (Table 1), a finding that can be explained by the fact that we had excluded *ETV6-RUNX1*-positive and HD cases with a relatively younger median age, from our fusion-negative control population.

Not only did we detect more *P2RY8-CRLF2*-positive cases than groups that used probably less sensitive RT-PCR- or FISH-based screening techniques,<sup>1,3,11</sup> we also noted that, irrespective of identical DNA and RNA/cDNA inputs, the amount of derived PCR products varied substantially. This observation led us to investigate whether these discrepancies might result from dissimilar proportions of *P2RY8-CRLF2*-positive cell clones in the various samples (Figure 1A-B).

### Quantification of *P2RY8-CRLF2* genomic fusions and *CRLF2* transcripts

We determined the respective sizes of the *P2RY8-CRLF2*-positive clones by quantifying the genomic breakpoint region with a qRT-PCR whose sensitivity reached a detection limit of  $1 \times 10^{-5}$  (supplemental Figure 2). To enable the comparison of the ensuing results with other less sensitive methods, such as FISH (general detection limit of 5%-10%; a respective comparison is shown in supplemental Table 2) and multiplex ligation-dependent probe amplification (detection limit of 20%), we split the samples into 2 groups using a 20% cut-off. Cases with equal or > 20% of genomic fusion-positive cells are referred to as major clones, whereas those with < 20% (including only 1 case with ~ 10% cells), which may be below the detection limit using the aforementioned methods, are referred to as minor subclones. The major clone-positive group comprised 18 (27%) and the minor subclone-positive group 49 (73%) of all fusion-positive cases (Table 1).

Next, we precisely quantified *CRLF2* transcripts under standardized conditions to enable their comparison with the quantity of fusion-positive cells. As shown in Figure 2A, these 2 parameters are highly correlated (correlation coefficient [CC], 0.43;  $P = .0018$ ).

Moreover, evaluation of the *CRLF2* expression levels in various subgroups revealed that a 50-fold overexpression clearly demarcates major clone-positive *P2RY8-CRLF2* cases from all *P2RY8-CRLF2*-negative cases. Only 20% to 30% of those with a minor subclone also have expression levels above this threshold, indicating that *CRLF2* in these leukemic clones might either be extremely up-regulated or, alternatively, that *CRLF2* expression in such instances is not entirely governed by the *P2RY8-CRLF2*-positive clone alone. The expression levels of the remaining minor subclone-positive cases largely overlap with those of HD cases. The lowest expression levels, in contrast, are seen in *ETV6-RUNX1*-positive cases, whereas those in a genetically undefined control group were marginally higher (supplemental Figure 3).

We also validated the results with a second system for measuring and calculating the relative amounts of *CRLF2* transcripts, and we found a nearly perfect match not only between the 2 methods (CC, -0.90;  $P < .0001$ ; Figure 2B) but also with the second method and the corresponding amounts of genomic fusion products (CC, -0.33;  $P = .0274$ ; Figure 2C).

### Predictive value of *P2RY8-CRLF2* in BCP-ALL cases

Because of the small number of DS cases in our study and the reported lack of a relapse predictive power of *P2RY8-CRLF2* in this particular entity, we excluded them from further analysis.<sup>2,10</sup> We first evaluated whether *P2RY8-CRLF2*-positive cases have indeed an increased relapse risk and how this may impair the OS in the selected cohort of our 248 cases. We found that *P2RY8-CRLF2*-positive non-DS ALL cases had a worse 5-year probability for overall survival (pOS), event-free survival (pEFS), and CIR than fusion-negative cases (pOS, 81% ± 7% vs 93% ± 2%,  $P = .057$ ; pEFS, 61% ± 8% vs 83% ± 3%,  $P = .009$ ; and CIR, 35% ± 8% vs 13 ± 3%,  $P = .008$ ; Figure 3A). The worse prognosis also remained valid when the total study cohort was analyzed (pOS, 81% ± 7% vs 94% ± 1%,  $P = .006$ ; pEFS, 61% ± 8% vs 87% ± 2%,  $P < .001$ ; and CIR, 35% ± 8% vs 9 ± 2%,  $P < .001$ ; Figure 3B). Next, we checked to which extent the size of the fusion-positive clone might modify the relapse risk, and we found that ALL cases with a fusion-positive minor subclone did as poorly as those with a major involvement (pOS, 80% ± 18% and 81% ± 7%,  $P = .869$ ; pEFS = 60% ± 9% and 63% ± 21%,  $P = .792$ ; and CIR, 38% ± 21% and 35% ± 9%,  $P = .825$ , for major and minor fusion-positive subclones, respectively; Figure 3C). We were not able to associate any particular cytogenetic abnormality with this increased relapse risk.

Because the predictive value of *P2RY8-CRLF2* is particularly pronounced in the non-SR/non-very-HR groups in the COG and the IR group in the AIEOP-BFM protocols,<sup>1,2,6-9</sup> we also analyzed the role of minimal residual disease risk group assignment as well as of applied treatment. We found that fusion-positive patients in the IR group had a significantly higher relapse risk than fusion-negative patients (CIR, 38% ± 10% vs 13% ± 4%;  $P = .015$ ; pOS, 82% ± 8% vs 94% ± 3%,  $P = .075$ ; pEFS, 62% ± 10% vs 85% ± 4%,  $P = .029$ ; Figure 3D). Again, the results remained valid when the fusion-positive cases were compared with the entire IR cohort of 324 cases (pOS, 82% ± 8% vs 95% ± 1%,  $P = .004$ ; pEFS, 62% ± 10% vs 87% ± 2%,  $P = .001$ ; and CIR, 38% ± 10% vs 10 ± 2%,  $P < .001$ ; Figure 3E). In addition, within the IR group, the size of the fusion harboring clone was completely irrelevant for the respective relapse risk and overall survival (pOS, 80% ± 18% vs 83% ± 9%,  $P = .884$ ; pEFS, 60% ± 22% vs 62% ± 12%,  $P = .853$ ; and CIR, 40% ± 22% vs 38 ± 12%;  $P = .855$ ; for major vs minor clone fusion-positive ALL cases; Figure 3F). Comparison of fusion-positive and fusion-negative ALL cases in the SR group revealed a similar trend but did not reach the necessary statistical significance (pOS, 92% ± 8% vs 100% ± 0%,  $P = .092$ ; pEFS, 68% ± 16% vs 93% ± 5%,  $P = .046$ ; and CIR, 24% ± 15% vs 7% ± 5%,  $P = .216$ ; supplemental Figure 3A). HR cases were not analyzed because the number was too small (Table 1).

### Assessment of the *P2RY8-CRLF2*-harboring clone stability in ALL relapse cases

Presuming that *P2RY8-CRLF2*-positive cell clones are directly involved in relapse development, they should have a certain proliferative or selective advantage, or both and it would be expected that they prevail in the respective relapses. We therefore studied 22 relapse samples that derived from 8 ALL cases with a fusion-positive major clone (36.4%) and 14 with a fusion-positive minor subclone at diagnosis. The clinical and biologic data of these cases are summarized in Table 2.

The behavior of *P2RY8-CRLF2*-positive clones was highly divergent and not at all predictable (Table 2 and supplemental Table 3). Only 4 of 8 cases with a fusion-positive major clone retained the same clone in a similar proportion at relapse. In 1 further case, the fusion-positive clone was still present at relapse but much smaller. In the remaining 3 cases a *P2RY8-CRLF2* fusion was neither detected by genomic PCR nor by RT-PCR in the relapse samples anymore. However, also none of the small *P2RY8-CRLF2*-positive clones that were present at diagnosis in 14 ALL cases evolved into a dominant clone at relapse. Instead, in 7 of them the fusion-positive subclone had disappeared and in another case it was replaced by a novel fusion-positive clone that had an entirely different breakpoint sequence. The PAR1 deletion at relapse was smaller (breakpoint 451 bp distal to *P2RY8* exon 1) than that at diagnosis (breakpoint 316 bp distal to *P2RY8* exon 1), precluding that it had derived from the initial fusion. In the remaining 6 cases, the fusion-positive clone reappeared in relapse, albeit in an amount that was proportional to that at diagnosis. Representative examples of the various patterns of the respective quantities of fusion-positive clones and their corresponding *CRLF2* transcript levels are depicted in Figure 4. The correlation between the *CRLF2* expression levels and the amount of genomic fusion in the relapse samples was similar to the correlation established at diagnosis.

### Backtracking the *P2RY8-CRLF2* fusion to birth

Given the apparent secondary nature of the *P2RY8-CRLF2* fusion and the relatively young age of the affected children at diagnosis (Table 1), we were particularly interested in checking whether this lesion might be already present at birth. We therefore used breakpoint-specific genomic PCR to amplify DNA that was extracted from the archived dried neonatal blood spots of 7 cases with a fusion-positive major clone, and we were able to identify the respective lesion in all of them. The amplification blots of qRT-PCR and gels of these cases are depicted in Figure 5A through I and in the corresponding standard curves in supplemental Figure 5A through F. In case 887, the 2 clonotypic TRDV2-TRAJ29 and IGHV2-IGHJ4 that were identified at initial diagnosis were also present at birth (supplemental Figure 6). Moreover, in case 873 that had 1 of the novel fusion breakpoints and therefore needed different PCR conditions, the comparison of native and whole genome-amplified Guthrie card DNA yielded identical results (Figure 5H-I).

### Discussion

Several study groups have analyzed the clinical and biologic relevance of *P2RY8-CRLF2* positivity, *CRLF2* overexpression, or both, albeit with only partly concordant results.<sup>1-8</sup> The comparison and interpretation of these data remain difficult not only because treatment regimens, patient numbers and observation periods varied but also because heterogeneous target populations, variable screening techniques, and ascertainment algorithms were used for these analyses. Moreover, all conclusions are based on the mutual but unproven understanding that the *P2RY8-CRLF2* fusion is a primary lesion that should mark the predominant leukemic clone both at diagnosis and, based on circumstantial evidence, also relapse. We therefore set out to explore these open issues and assumptions in an unbiased systematic and comprehensive manner.



Our analyses with PCR methods that were optimized for the high-sensitivity quantification of *P2RY8-CRLF2* fusions at the DNA and RNA level, as well as the corresponding *CRLF2* expression levels in a representative cohort of childhood ALL patients at diagnosis and relapse and also in DNA from neonatal blood spots, revealed a clear-cut relationship between these parameters. Our most important discovery was the unexpected heterogeneity of *P2RY8-CRLF2*-positive clone sizes and their astonishing inert behavior. This finding has important biologic and clinical implications, especially if size—these clones are usually very small—is being taken into account. It not only necessitates the reinterpretation of *CRLF2* expression data and requires a critical reconsideration of the envisioned role of the respective clones in disease and relapse development as well as of *P2RY8-CRLF2* as a clinical risk parameter but also demands a careful reassessment of the appropriateness of potential therapeutic interventions that might be developed to target *P2RY8-CRLF2*-associated signal transduction pathways.<sup>23</sup>

To increase the sensitivity of both DNA- and RNA-based *P2RY8-CRLF2* detection methods, we first modified published primer sets<sup>2</sup> and adapted the PCR conditions accordingly. The concomitant evaluation of the respective fusion products on the DNA and RNA level eventually led to the identification of 2 new breakpoints, which increased the number of cases that are now detectable on the genomic level by 10%. Moreover, the complete concordance between these 2 complementary approaches reassured us that we had indeed detected all cases. As evidenced by our discovery rate, which was approximately twice as high as the rate achieved in previous studies, the combined application of DNA/RNA screening definitely surpasses any other currently applied ascertainment procedures.<sup>1-5,8,10,11</sup>

The precise quantification of *P2RY8-CRLF2*-positive cell clones at the genomic level at diagnosis uncovered 2 distinct groups with large and small clone sizes, respectively. Their distribution at diagnosis as well as their involvement in disease recurrence was highly erratic. Out of the original 8 major clones 4 persisted, 3 disappeared, and 1 reverted to a minor clone. In contrast, none of the minor subclones evolved into a major clone, 8 were lost, 5 persisted, and 1 was replaced with a clone that had a different breakpoint (Table 2). Of the only 2 matched diagnosis/relapse pairs that had been analyzed previously, both had apparently also lost the *P2RY8-CRLF2*-positive clone at relapse.<sup>8</sup> In line with various other leukemia clone-specific markers, we also confirmed that at least in cases with a major *P2RY8-CRLF2*-positive clone the fusion is already present at birth.<sup>16-18,24-27</sup> Apart from that, however, *P2RY8-CRLF2*-positive clones do not seem to have any particular proliferative or selective advantage and therefore also not the necessary fitness to evolve into a disease-relevant relapse clone. This view is supported by experiments showing in various model systems that neither fusion nor *CRLF2* overexpression alone is sufficient to transform cells without the concomitant expression of certain activating mutations, such as those affecting the *JAK2*, *CRLF2*, or *IL7R* genes.<sup>2-4,10,11,28</sup>

We also found a high concordance rate between *P2RY8-CRLF2*-positive clone sizes and the corresponding *CRLF2* expression levels. The fact that this was achieved with 2 different transcript quantification techniques—one technique relating the *CRLF2* normalized expression level to the expression levels of peripheral blood MNCs from healthy donors and

the other relating the expression to the transcript level of an internal housekeeping control gene—proved that both approaches are valid and that the results are also interchangeable. All cases with a major clone as well as 20% to 30% of those with a minor clone expressed *CRLF2* at least 50-fold higher than peripheral blood MNCs, a level that was not reached by any of the *P2RY8-CRLF2*-negative controls and therefore served as our cut-off for overexpression. Although our control group was relatively small ( $n = 54$ ), we did not identify any *CRLF2*-overexpressing cases. This observation is in sharp contrast to several other studies that found that up to half of the *CRLF2*-overexpressing cases lack *CRLF2* rearrangements.<sup>1,4-6,8,29</sup> The common attribute of such *CRLF2*-overexpressing cases without *CRLF2* rearrangement is a “BCR-ABL-like” gene expression profile whose special characteristic is an activated JAK/STAT pathway.<sup>4,7</sup> Apart from this currently difficult to understand discrepancy, however, the established tight association between clone size and expression level can probably explain several other incongruities that are commonly encountered in studies that merely tried to correlate *P2RY8-CRLF2* positivity with expression levels without the respective quantification.

Finally, our most perplexing result was that the overall disease recurrence risk of our *P2RY8-CRLF2*-positive cases was within the range that had been reported previously in other AIEOP/BFM studies<sup>1,8</sup>; notwithstanding the fact that we identified nearly twice as many cases, most of which had negligible clone sizes at diagnosis and no participation in disease recurrence.

We are now confronted with 3 partly conflicting and thus difficult to harmonize views of how *P2RY8-CRLF2* fusions might shape the various levels of the respective disease process, namely a genomic, a clonal and a clinical level.

*CRLF2* rearrangements are the first known step in a transformation process that further requires *CRLF2* overexpression and at least certain cooperating mutations in specific genes to attain the biochemical and functional changes that, typically, also comprise activated JAK/STAT and PI3K/mTOR signaling pathways.<sup>2,10,23,28</sup> The cases used in these functional studies were selected from expression profiles. It can therefore be safely assumed that they had either a *P2RY8-CRLF2*-positive major clone or an especially high expressing *IGH@-CRLF2* fusion, the latter of which is also found in the cell lines used.<sup>3,23</sup>

In contrast to what might intuitively be expected from such transformed cells, our quantitative analyses of *P2RY8-CRLF2*-positive cell clones do not support the notion that these functional changes really equip these cells with the necessary fitness to successfully compete with their *P2RY8-CRLF2*-negative leukemic counterparts *in vivo*. Thus, although the *P2RY8-CRLF2* fusions may drive the cellular transformation process, it seems highly improbable that they also drive the entire leukemic process. Instead, we suggest that the *P2RY8-CRLF2* fusion is virtually always a secondary lesion in form of a passenger mutation, a notion that is strongly corroborated by the fact that these lesions always require concomitant mutations to even become functionally relevant. To explain the fact that, contrary to what would be expected and deduced from our laboratory results, *P2RY8-CRLF2* fusions are nevertheless a clear clinical risk factor, 1 or several higher ranking yet unidentified primary changes have to be invoked that should be closely associated with or

even trigger the manifestation of *CRLF2* rearrangements. Considering the particularly strong tendency of ALL patients with a constitutional trisomy 21 to acquire *CRLF2* rearrangements, such a concept is perhaps not as far-fetched as it might seem at first sight.<sup>2,10</sup> It is worth noting that such an acquired initiating change probably already exists in the form of an intrachromosomal amplification of chromosome 21 (iAMP21). With a concurrence rate of 25%, it is at present the only known primary abnormality that has a nearly analogous affinity with *P2RY8-CRLF2* fusions as a constitutional trisomy 21.<sup>5</sup> A remote alternative explanation for an independent role of minor *P2RY8-CRLF2*-positive clones would be that they alone could perhaps render their fusion-negative leukemic counterparts resistant through a paracrine route in a similar manner as has been demonstrated for minor mutant *BCR-ABL*-positive clones in comparable situations.<sup>30</sup> However, the absence of *P2RY8-CRLF2*-positive clones in most relapses hardly supports such a possibility.

We conclude that our comprehensive detailed quantitative analyses of *P2RY8-CRLF2*-positive leukemias revealed some novel and intriguing insight into the performance of the involved cell clones that were not readily deducible from the predicted function of fusion-carrying cells. Conversely, the respective distribution pattern and inert behavior of such clones still stands in sharp contrast with the clinical experience of *P2RY8-CRLF2* as HR parameter. Thus, our findings deliver some valid answers and good explanations for some hitherto controversial issues that arose from the heterogeneous data sets, and they also open up new venues for further research with some important implications for the organization of experimental setups as well as the diagnostic workup and clinical management of patients. Taking into account that *P2RY8-CRLF2* is most likely a pure secondary change that is usually present only in small clones and is commonly lost in relapses, it seems unlikely that therapies aiming to eliminate such clones can indeed prevent disease recurrences, at least in the currently proposed manner.<sup>23</sup> Finally, we believe that precise quantitative information about clone sizes and expression levels will be indispensable in the future to reasonably and accurately interpret and compare experimentally, diagnostically and clinically obtained *CRLF2* data.

## Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

## Acknowledgments

The authors thank all physicians, nurses, parents, and patients in Austria who made this work possible; Astrid Mecklenbräuer and Marion Zeginigg for providing clonotypic Ig/TCR rearrangements; and Evgenia Glogova for statistical analysis.


This work was supported in part by the ÖNB Jubiläumsfonds 14129 (M.M.), Clinical Investigator-driven grant 2010-03 (A.A., G.M., O.A.H., R.P.-G.), and the Help and Hope Foundation in collaboration with KIK Textilien und Non-Food GmbH Austria. This is a project of the international BFM study group.

## References

1. Cario G, Zimmermann M, Romey R, et al. Presence of the *P2RY8-CRLF2* rearrangement is associated with a poor prognosis in non-high-risk precursor B-cell acute lymphoblastic leukemia in


- children treated according to the ALL-BFM 2000 protocol. *Blood*. 2010; 115(26):5393–5397. [PubMed: 20378752]
2. Mullighan CG, Collins-Underwood JR, Phillips LA, et al. Rearrangement of CRLF2 in B-progenitor- and Down syndrome-associated acute lymphoblastic leukemia. *Nat Genet*. 2009; 41(11):1243–1246. [PubMed: 19838194]
  3. Russell LJ, Capasso M, Vater I, et al. Deregulated expression of cytokine receptor gene, CRLF2, is involved in lymphoid transformation in B-cell precursor acute lymphoblastic leukemia. *Blood*. 2009; 114(13):2688–2698. [PubMed: 19641190]
  4. Yoda A, Yoda Y, Chiaretti S, et al. Functional screening identifies CRLF2 in precursor B-cell acute lymphoblastic leukemia. *Proc Natl Acad Sci U S A*. 2010; 107(1):252–257. [PubMed: 20018760]
  5. Ensor HM, Schwab C, Russell LJ, et al. Demographic, clinical, and outcome features of children with acute lymphoblastic leukemia and CRLF2 deregulation: results from the MRC ALL97 clinical trial. *Blood*. 2011; 117(7):2129–2136. [PubMed: 21106984]
  6. Chen IM, Harvey RC, Mullighan CG, et al. Outcome modeling with CRLF2, IKZF1, JAK, and minimal residual disease in pediatric acute lymphoblastic leukemia: a Children's Oncology Group study. *Blood*. 2012; 119(15):3512–3522. [PubMed: 22368272]
  7. Harvey RC, Mullighan CG, Chen IM, et al. Rearrangement of CRLF2 is associated with mutation of JAK kinases, alteration of IKZF1, Hispanic/Latino ethnicity, and a poor outcome in pediatric B-progenitor acute lymphoblastic leukemia. *Blood*. 2010; 115(26):5312–5321. [PubMed: 20139093]
  8. Palmi C, Vendramini E, Silvestri D, et al. Poor prognosis for P2RY8-CRLF2 fusion but not for CRLF2 over-expression in children with intermediate risk B-cell precursor acute lymphoblastic leukemia. *Leukemia*. 2012; 26(10):2245–2253. [PubMed: 22484421]
  9. Attarbaschi A, Morak M, Cario G, et al. Treatment outcome of CRLF2 -rearranged childhood acute lymphoblastic leukaemia: a comparative analysis of the AIEOP-BFM and UK NCRI-CCLG study groups. *Br J Haematol*. 2012; 158(6):772–777. [PubMed: 22816614]
  10. Hertzberg L, Vendramini E, Ganmore I, et al. Down syndrome acute lymphoblastic leukemia, a highly heterogeneous disease in which aberrant expression of CRLF2 is associated with mutated JAK2: a report from the International BFM Study Group. *Blood*. 2010; 115(5):1006–1017. [PubMed: 19965641]
  11. Dyer MJ, Akasaka T, Capasso M, et al. Immunoglobulin heavy chain locus chromosomal translocations in B-cell precursor acute lymphoblastic leukemia: rare clinical curios or potent genetic drivers? *Blood*. 2010; 115(8):1490–1499. [PubMed: 20042721]
  12. Chapiro E, Russell L, Lainey E, et al. Activating mutation in the TSLPR gene in B-cell precursor lymphoblastic leukemia. *Leukemia*. 2010; 24(3):642–645. [PubMed: 19907440]
  13. Conter V, Bartram CR, Valsecchi MG, et al. Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOP-BFM ALL 2000 study. *Blood*. 2010; 115(16):3206–3214. [PubMed: 20154213]
  14. Flohr T, Schrauder A, Cazzaniga G, et al. Minimal residual disease-directed risk stratification using real-time quantitative PCR analysis of immunoglobulin and T-cell receptor gene rearrangements in the international multicenter trial AIEOP-BFM ALL 2000 for childhood acute lymphoblastic leukemia. *Leukemia*. 2008; 22(4):771–782. [PubMed: 18239620]
  15. van der Velden VH, Cazzaniga G, Schrauder A, et al. Analysis of minimal residual disease by Ig/TCR gene rearrangements: guidelines for interpretation of real-time quantitative PCR data. *Leukemia*. 2007; 21(4):604–611. [PubMed: 17287850]
  16. Fischer S, Mann G, Konrad M, et al. Screening for leukemia- and clone-specific markers at birth in children with T-cell precursor ALL suggests a predominantly postnatal origin. *Blood*. 2007; 110(8):3036–3038. [PubMed: 17557895]
  17. Panzer-Grümayer ER, Fasching K, Panzer S, et al. Nondisjunction of chromosomes leading to hyperdiploid childhood B-cell precursor acute lymphoblastic leukemia is an early event during leukemogenesis. *Blood*. 2002; 100(1):347–349. [PubMed: 12070048]
  18. Fasching K, Panzer S, Haas OA, Marschalek R, Gadner H, Panzer-Grumayer ER. Presence of clone-specific antigen receptor gene rearrangements at birth indicates an in utero origin of diverse

- types of early childhood acute lymphoblastic leukemia. *Blood*. 2000; 95(8):2722–2724. [PubMed: 10753857]
19. Kaplan ELMP. Nonparametric estimation from incomplete observations. *J Am Stat Assoc*. 1958; 53(282):4.
  20. Kalbfleisch, JDPR. *The Statistical Analysis of Failure Time Data*. 1st Ed.. John Wiley and Sons; New York, NY: 1988. p. 163-188.
  21. Gray R. A class of K-sample tests for comparing the cumulative incidence of a competing risk. *Ann Stat*. 1988; 16(3):1141–1154.
  22. Tsai AG, Yoda A, Weinstock DM, Lieber MR. t(X; 14)(p22;q32)/t(Y;14)(p11;q32) CRLF2-IGH translocations from human B-lineage ALLs involve CpG-type breaks at CRLF2, but CRLF2/P2RY8 intrachromosomal deletions do not. *Blood*. 2010; 116(11):1993–1994. [PubMed: 20847213]
  23. Tasian SK, Doral MY, Borowitz MJ, et al. Aberrant STAT5 and PI3K/mTOR pathway signaling occurs in human CRLF2-rearranged B-precursor acute lymphoblastic leukemia. *Blood*. 2012; 120(4):833–842. [PubMed: 22685175]
  24. Eguchi-Ishimae M, Eguchi M, Kempinski H, Greaves M. NOTCH1 mutation can be an early, prenatal genetic event in T-ALL. *Blood*. 2008; 111(1):376–378. [PubMed: 17901244]
  25. Maia AT, van der Velden VH, Harrison CJ, et al. Prenatal origin of hyperdiploid acute lymphoblastic leukemia in identical twins. *Leukemia*. 2003; 17(11):2202–2206. [PubMed: 12931229]
  26. Taub JW, Konrad MA, Ge Y, et al. High frequency of leukemic clones in newborn screening blood samples of children with B-precursor acute lymphoblastic leukemia. *Blood*. 2002; 99(8):2992–2996. [PubMed: 11929791]
  27. Wiemels JL, Cazzaniga G, Daniotti M, et al. Prenatal origin of acute lymphoblastic leukaemia in children. *Lancet*. 1999; 354(9189):1499–1503. [PubMed: 10551495]
  28. Shochat C, Tal N, Bandapalli OR, et al. Gain-of-function mutations in interleukin-7 receptor-alpha (IL7R) in childhood acute lymphoblastic leukemias. *J Exp Med*. 2011; 208(5):901–908. [PubMed: 21536738]
  29. Harvey RC, Mullighan CG, Wang X, et al. Identification of novel cluster groups in pediatric high-risk B-precursor acute lymphoblastic leukemia with gene expression profiling: correlation with genome-wide DNA copy number alterations, clinical characteristics, and outcome. *Blood*. 2010; 116(23):4874–4884. [PubMed: 20699438]
  30. Liu J, Joha S, Idziorek T, et al. BCR-ABL mutants spread resistance to non-mutated cells through a paracrine mechanism. *Leukemia*. 2008; 22(4):791–799. [PubMed: 18216868]



**Figure 1. Identification of *P2RY8-CRLF2* in childhood BCP-ALL cases**


(A) PCR products of the genomic *P2RY8-CRLF2* fusion of representative cases. Patient identification is indicated at the top of the gel: ad, nontemplate control; pB, peripheral blood MNCs; and SM, size marker. Left part of the gel (samples 360-903) shows PCR products from cases that were later defined as harboring the *P2RY8-CRLF2* fusion in a major clone. Right part of the gel (samples 460-906) shows PCR products from ALL cases with *P2RY8-CRLF2* in a minor subclone. (B) PCR for the fusion transcripts of corresponding cases. Note that sample 365 had no genomic PCR product but a distinct band for the transcript. (C) PCR products of the 6 cases with the newly discovered breakpoints upstream of *CRLF2*. A vertical line was inserted to indicate that different gels, run in parallel, from identical experiments were pasted together.



**Figure 2. Quantification of *P2RY8-CRLF2* genomic breakpoints and *CRLF2* transcripts**  
 (A) Relation between abundance of genomic fusion and *CRLF2* expression in 56 *P2RY8-CRLF2*-positive ALL cases. Genomic DNA was used for the fusion (triangles; empty symbols, cases with *P2RY8-CRLF2* in a minor subclone [ $< 20\%$  of leukemia population]; filled symbols, cases with *P2RY8-CRLF2* in a major clone [ $\geq 20\%$  of leukemia population]); and mRNA for *CRLF2* transcript quantification (squares). Black symbols indicate cases in remission; and red, relapse cases. (Left) Y-axis: normalized *CRLF2* levels plotted relative to *CRLF2* expression in peripheral blood MNC. (Right) Amounts of genomic fusion in percentage of the leukemia population. X-axis: ALL cases ordered from the lowest to highest *CRLF2* expression. A dashed horizontal line has been inserted at the 50-fold *CRLF2* overexpression defined by the lowest expression in cases with the fusion in a major population of the leukemia clone and no expression in all other genetic ALL subtypes. The black vertical line separates cases with low (left) and high (right) *CRLF2* expression. (B) Quantification of *CRLF2* expression by real-time PCR: comparison of 2 methods. (Left) Y-axis: Ct values of *CRLF2* expression using the Applied Biosystems kit and the criteria for high expression of Ct = 8.0. (Right) Fold changes of *CRLF2* expression, as in panel A. X-axis: ALL cases ordered from the lowest to highest percentage of *CRLF2* expression as in


panel A. Two horizontal lines were inserted to show the respective limits for overexpression by each method; dashed, the 50-fold overexpression as in panel A; dotted, *CRLF2* overexpression at Ct = 8.0. (C) Relation between abundance of genomic fusion and *CRLF2* expression by the inventoried assays for *CRLF2* and *EEF2*. The dotted horizontal line indicates the *CRLF2* expression at Ct 8.0 as in panel B. ALL cases ordered from the lowest to highest *CRLF2* expression as in panel B. The black vertical line separates cases with low (left) and high (right) *CRLF2* expression.






**Figure 3. Clinical outcome of children with BCP-ALL enrolled in the BFM ALL 2000 protocol in Austria according to *P2RY8-CRLF2***

Kaplan-Meier estimates of 5-year pOS (left), pEFS (middle), and CIR (cumulative incidence; right) according to the presence of *P2RY8-CRLF2* and its proportion in the leukemia of 248 screened non-DS cases (A,C) and of all 530 non-DS cases (B) enrolled in the treatment study. Analogous analyses of ALL cases treated according to the IR treatment arm (D-F).



**Figure 4. Patterns of genomic *P2RY8-CRLF2* and *CRLF2* transcripts of fusion-positive ALL relapse cases**

The 6 different patterns of clonal relation between initial diagnosis (D) and relapse (R) leukemia are depicted. (A) Genomic PCR products for *P2RY8-CRLF2* in representative cases. Sample identification is indicated at the top of the figure: ad, nontemplate control; pB, peripheral blood MNCs; and SM, size marker. Cases 1, 3, and 737 harbor the fusion in a major clone at initial diagnosis, and it was either conserved (1), lost (3), or reduced to a minor subclone (737) at relapse. In cases 810, 564, and 243 with a fusion-positive minor subclone at initial diagnosis, the fusion was also either lost (810), preserved (243), or replaced by a different fusion (564) at relapse. Quantification of the genomic *P2RY8-CRLF2* fusion (indicated in percentage of leukemia cells at the y-axis; B) and the corresponding *CRLF2* transcript levels (fold changes of normalized expression of the samples over the expression in peripheral blood MNCs; C). Sample identification is given at the bottom of the graph.



**Figure 5. Detection of the *P2RY8-CRLF2* in neonatal blood spots**

Amplification plots of the qRT-PCR of genomic *P2RY8-CRLF2* using whole genome–amplified genomic Guthrie card DNA of 6 ALL cases: 400 (A), 737 (B), 802 (C), 833 (D), 841 (E), and 887 (F). Standard curves showing a quantitative range of  $1 \times 10^{-5}$  (blue) and PCR products of Guthrie card DNA from 4 aliquots in triplicates (red). PCR products for *P2RY8-CRLF2* with a newly identified genomic breakpoint of case 873. (G) Amplification of the genomic breakpoint. Dilution series of genomic leukemia DNA. (Left) First round. (Right) Second round. The fusion can be detected at the single cell level at  $1 \times 10^{-5}$  (lane 5). Lane 1, size marker; lane 2, H<sub>2</sub>O; lane 3, DNA mix from peripheral blood MNCs of healthy donors; and lanes 4 to 9, 10-log dilutions from  $1 \times 10^{-6}$  to  $1 \times 10^{-1}$ . Amplification of *P2RY8-CRLF2* in native (H) and whole genome–amplified Guthrie card (I) DNA. Lane 1, size marker; lane 2, H<sub>2</sub>O; lane 3, control DNA mix; and lanes 4 to 10, Guthrie cards DNA from a newborn who did not develop ALL later. a to i, PCR products from aliquots of the patients' Guthrie card DNA.

**Table 1**  
**Patient characteristics and response to treatment according to *P2RY8-CRLF2* fusion in 268 patients with childhood BCP-ALL**

	<i>P2RY8-CRLF2</i>			<i>P2RY8-CRLF2</i> +		<i>P</i>
	Positive	Negative	<i>P</i>	Major sub/clone*	Minor subclone*	
No. of patients (%)	67 (25.0)	201 (75.0)		18 (6.7)	49 (18.3)	
<b>Sex (%)</b>			.724			.974
Male	37 (55.2)	106 (52.7)		10 (55.6)	27 (55.1)	
Female	30 (44.8)	95 (47.3)		8 (44.4)	22 (44.9)	
<b>Age, y (%)</b>			.003			.11
1-10	55 (82.1)	126 (62.7)		17 (94.4)	38 (77.6)	
10	12 (17.9)	75 (37.3)		1 (5.6)	11 (22.4)	
<b>WBC count (%)</b>			.561			.872
< 50 000/ $\mu$ L	55 (82.1)	171 (85.1)		15 (83.3)	40 (81.6)	
50 000/ $\mu$ L	12 (17.9)	30 (14.9)		3 (16.7)	9 (18.4)	
<b>Pred response (%)</b>			.279			.796
Good	64 (95.5)	183 (91.0)		17 (94.4)	47 (95.9)	
Poor	3 (4.5)	17 (8.5)		1 (5.6)	2 (4.1)	
Not available	0 (0.0)	1 (0.5)		0 (0.0)	0 (0.0)	
<b>Treatment arm (%)</b>			.343			.671
Standard risk	19 (28.4)	39 (19.4)		6 (33.3)	13 (26.6)	
Intermediate risk	39 (58.2)	129 (64.2)		11 (61.1)	28 (57.1)	
High risk	7 (10.4)	29 (14.4)		1 (5.6)	6 (12.2)	
Death before risk stratification	2 (3.0)	3 (1.5)		0 (0.0)	2 (4.1)	
Other	0 (0.0)	1 (0.5)		0 (0.0)	0 (0.0)	
<b>DS (%)</b>			< .001			.009
Yes	15 (22.4)	5 (2.5)		8 (44.4)	7 (14.3)	
No	52 (77.6)	196 (97.5)		10 (55.6)	42 (85.7)	
<b>Relapse (%)</b>			.006			.137
Yes	16 (23.9)	21 (10.4)		2 (11.1)	14 (28.6)	
No	51 (76.1)	180 (89.6)		16 (88.9)	35 (71.4)	
Incidence of relapse non-DS cases (CIR) <sup>†</sup> (%)	13/52 (35 $\pm$ 8)	21/196 (13 $\pm$ 3)	.008	2/10 (38 $\pm$ 21)	11/42 (35 $\pm$ 9)	.825
Standard risk	2/13 (24 $\pm$ 15)	2/37 (7 $\pm$ 5)	.216	0/3	2/10 (24 $\pm$ 15)	.739
Intermediate risk	9/31 (38 $\pm$ 10)	14/127 (13 $\pm$ 4)	.015	2/6 (40 $\pm$ 22)	7/25 (38 $\pm$ 12)	.855
High risk	2/7 (50 $\pm$ 25)	5/28 (22 $\pm$ 9)	.540	0/1 (0)	2/6 (50 $\pm$ 25)	n.a.
Median follow-up, y (range)	5.1 (1.1-10.9)	5.2 (1.1-10.6)	n.a.	5.4 (1.5-9.8)	5.1 (1.1-10.9)	n.a.

n.a. indicates not analyzed.

\* Clonal size definition: major,  $\geq$  20%; minor, < 20%.

<sup>†</sup> Five-year cumulative incidence of relapse is given in parentheses. Graytest was used to estimate strata homogeneity.

**Table 2**  
**Clinical characteristic of 22 *P2RY8-CRLF2*-positive relapse cases**

Pt ID	Sex	Age at dx, y	MRD	Rem, mo	Rel site	Source	Clonal stability of <i>P2RY8-CRLF2</i>
<b><i>P2RY8-CRLF2</i> major clone</b>							
715	M	8.90	IR	17	BM	AT	Conserved
737	M	9.50	IR	25	BM + CNS	AT	Reduced to minor subclone
1*	F	2.00	IR	33	BM	DE	Lost
4	F	1.40	IR	42	BM	DE	Lost
2*	M	8.70	IR	63	BM	DE	Conserved
3	M	4.60	LR	65	BM	DE	Lost
5*	F	4.10	IR	67	BM	DE	Conserved
6	F	2.70	LR	98	BM	DE	Conserved
<b><i>P2RY8-CRLF2</i> minor subclone</b>							
775	M	13.20	IR	11	BM	AT	Lost
391	F	12.70	IR	12	BM	AT	Conserved
814	F	4.60	LR	18	BM	AT	Lost
721	M	2.50	IR	20	testis	AT	Conserved
778	M	4.20	IR	20	BM	AT	Lost
810	M	4.90	IR	28	BM + CNS	AT	Lost
579	M	1.30	IR	35	BM	AT	Lost
460	F	5.70	IR	36	BM	AT	Lost
571	M	9.20	IR	44	BM	AT	Lost
456	M	12.00	IR	48	BM	AT	Conserved
545	M	4.70	LR	55	BM	AT	Lost
564*	M	8.25	LR	55	BM	AT	Different minor subclone
417*	F	9.75		60	BM	AT	Conserved
243*	F	10.40	IR	71	BM	AT	Conserved

Pt indicates patient; dx, initial diagnosis; MRD, minimal residual disease risk classification; Rem, remission; Rel, relapse; BM, bone marrow; and CNS, central nervous system.

\* Down syndrome.